Mizuho Securities questions if the obesity trade for the sto...
Mizuho Securities questions if the obesity trade for the stock is nearing its end. Management's lack of bullishness on MariTide, and the lead of Eli Lilly and Novo, puts pressure on Amgen to stand out. Leerink downgraded Amgen due to high expectations from its weight loss drug R&D program.
Amgen Stock Suffers Worst Day in Over 2-1/2 Years as Analysts Debate Weight Loss Prospects
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment